Author:
Li Guo-Sheng,Zhang Wei,Huang Wan-Ying,He Rong-Quan,Huang Zhi-Guang,Gan Xiang-Yu,Yang Zhen,Dang Yi-Wu,Kong Jin-Liang,Zhou Hua-Fu,Chen Gang
Abstract
Abstract
Background
Centrosomal protein 55 (CEP55) plays a significant role in specific cancers. However, comprehensive research on CEP55 is lacking in pan-cancer.
Methods
In-house and multi-center samples (n = 15,823) were used to analyze CEP55 in 33 cancers. The variance of CEP55 expression levels among tumor and control groups was evaluated by the Wilcoxon rank-sum test and standardized mean difference (SMD). The clinical value of CEP55 in cancers was assessed using receiver operating characteristic (ROC) curves, Cox regression analysis, and Kaplan-Meier curves. The correlations between CEP55 expression and the immune microenvironment were explored using Spearman’s correlation coefficient.
Results
The data of clustered regularly interspaced short palindromic repeats confirmed that CEP55 was essential for the survival of cancer cells in multiple cancer types. Elevated CEP55 mRNA expression was observed in 20 cancers, including glioblastoma multiforme (p < 0.05). CEP55 mRNA expression made it feasible to distinguish 21 cancer types between cancer specimens and their control samples (AUC = 0.97), indicating the potential of CEP55 for predicting cancer status. Overexpression of CEP55 was correlated with the prognosis of cancer individuals for 18 cancer types, exhibiting its prognostic value. CEP55 expression was relevant to tumor mutation burden, microsatellite instability, neoantigen counts, and the immune microenvironment in various cancers (p < 0.05). The expression level and clinical relevance of CEP55 in cancers were verified in lung squamous cell carcinoma using in-house and multi-center samples (SMD = 4.07; AUC > 0.95; p < 0.05).
Conclusion
CEP55 may be an immune-related predictive and prognostic marker for multiple cancers, including lung squamous cell carcinoma.
Funder
Guangxi Medical University “Future Academic Star” Scientific Research Project
the Key Research Program of Guangxi Science and Technology Department
Guangxi Zhuang Autonomous Region Medical Health Appropriate Technology Development and Application Promotion Project
Guangxi Medical High-level Key Talents Training “139” Program
Guangxi Higher Education Undergraduate Teaching Reform Project
Guangxi Educational Science Planning Key Project
Guangxi Medical University Key Textbook Construction Project
Publisher
Springer Science and Business Media LLC
Subject
Pulmonary and Respiratory Medicine
Reference64 articles.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021;71(3):209–49.
2. Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B, et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nature reviews Cancer. 2017;17(5):286–301.
3. Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nature reviews Drug discovery. 2019;18(3):175–96.
4. van den Bulk J, Verdegaal EM, de Miranda NF. Cancer immunotherapy: broadening the scope of targetable tumours. Open biology. 2018;8(6).
5. Blum A, Wang P, Zenklusen JC. SnapShot: TCGA-Analyzed Tumors. Cell. 2018;173(2):530.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献